Skip to content

The effects of different doses of topical tranexamic acid on postoperative blood loss, inflammation, coagulation, fibrinolysis, and knee function in patients with rheumatoid synovitis undergoing arthroscopic debridement

The effects of different doses of topical tranexamic acid on postoperative blood loss, inflammation, coagulation, fibrinolysis, and knee function in patients with rheumatoid synovitis undergoing arthroscopic debridement

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022280
Enrollment
Unknown
Registered
2019-04-03
Start date
2019-04-04
Completion date
Unknown
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid synovitis

Interventions

B:Topical TXA 1g/100ml
C:Topical TXA 2g/100ml
D:Topical TXA 3g/100ml

Sponsors

Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The patients with rheumatoid synovitis undergoing arthroscopic debridement; (2) Normal platelet and coagulation function preoperatively; (3) Normal intravenous ultrasound in the lower extremities preoperatively; (4) To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Systemic infections such as pulmonary infection or urinary tract infection are not controlled preoperatively; (2) Abnormal immune function or combined immune-related disease preoperatively; (3) Abnormal inflammatory index preoperatively (C-reactive protein >20 mg/L); (4) Abnormal fibrinolysis index preoperatively (FDP > 5mg/L); (5) Discontinuation of oral anticoagulants or aspirin less than 1 week; (6) Allergy to tranexamic acid (TXA) or dexamethasone or have contraindications; (7) Patients at high risk of thrombosis; (8) History of deep vein thrombosis (VTE, calf muscle vein thrombosis or superficial vein thrombosis, pulmonary embolism); (9) serious liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Blood loss;

Secondary

MeasureTime frame
ESR, CRP, IL-6,IL-10;Hb;Hct;DVT, PE;Transfusion;Swelling;VAS pain score;color Doppler Ultrasonic (CDU) examination in lower extremity;Rheumatoid index;ROM;IKDC;Lysholm;Muscle strength;Function MRI;Coagulation index;Drainage;Satisfaction scores;ESR, CRP, IL-6 in drainage;Analysis of joint fluid composition;protein chemistry and enzyme mechanism/Metabolism;TXA metabolism and outcome;

Countries

China

Contacts

Public ContactJian Li

West China Hospital, Sichuan University

18980601388@163.com+86 18980601388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026